Global prevailing and emerging pediatric pneumococcal serotypes

Expert Review of Vaccines

Volumn 10, Issue 1, 2011, Pages 109-129

  McIntosh, E David G ^a   Reinert, Ralf R ^b  

^a Novartis Vaccines   (Netherlands)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

bacteremia; invasive pneumococcal disease; IPD; meningitis; pneumococcal conjugate vaccine; pneumococcus; serotypes; Streptococcus pneumoniae

Indexed keywords

7 VALENT PNEUMOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AFRICA; ARGENTINA; AUSTRALIA; AUSTRIA; BANGLADESH; BELGIUM; BRAZIL; CANADA; CHILE; CHINA; COLOMBIA; DENMARK; EUROPE; FINLAND; FRANCE; GREECE; HAEMOPHILUS INFLUENZAE; HUMAN; JAPAN; KOREA; MEXICO; MIDDLE EAST; NETHERLANDS; NORTH AFRICA; NORTH AMERICA; NORWAY; PERU; PHILIPPINES; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; POLAND; PORTUGAL; PRIORITY JOURNAL; REVIEW; SEROEPIDEMIOLOGY; SEROPREVALENCE; SEROTYPE; SOUTH AND CENTRAL AMERICA; SPAIN; STREPTOCOCCUS PNEUMONIAE; SWITZERLAND; TAIWAN; UNITED KINGDOM; UNITED STATES; URUGUAY;

BACTERIAL TYPING TECHNIQUES; HUMANS; INCIDENCE; PANDEMICS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE;

EID: 78650497300     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.145     Document Type: Review

References (238)

1. Centers for Disease Control and Prevention. Preventing pneumococcal disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep. 49(RR-9), 1-35 (2000).
2. Centers for Disease Control and Prevention. Progress in introduction of pneumococcal conjugate vaccine -worldwide, 2000-2008. MMWR Morb. Mortal. Wkly Rep. 57, 1148-1151 (2008).
3. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease -United States, 1998-2003. MMWR Morb. Mortal. Wkly Rep. 54, 893-897 (2005).
4. Kaplan SL, Mason EO, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children's hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics 113, 443-449 (2004).
5. Hsu HE, Shutt KA, Moore MR et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N. Engl. J. Med. 360, 244-256 (2009).
6. Kellner JD, Church DL, MacDonald J, Tyrrell GJ, Scheifele D. Progress in the prevention of pneumococcal infection. Can. Med. Assoc. J. 173, 1149-1151 (2005).
7. Roche PW, Krause V, Cook H et al.; Pneumococcal Working Party of the Communicable Diseases Network Australia. Invasive pneumococcal disease in Australia, 2006. Commun. Dis. Intell. 32, 18-30 (2008).
8. Dubos F, Marechal I, Husson MO, Courouble C, Aurel M, Martinot A; Hospital Network for Evaluating the Management of Common Childhood Diseases. Decline in pneumococcal meningitis after the introduction of the heptavalent-pneumococcal conjugate vaccine in northern France. Arch. Dis. Child. 92, 1009-1012 (2007).
9. Van der Linden M, Imoehl M, Reinert R. Surveillance of IPD in children in Germany 2004-2008, frst results of the German national immunization program for PCV7. Presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA, 25-28 October 2008.
10. Vestrheim DF, Løvoll Ø, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26, 3277-3281 (2008).
11. Aristegui J, Bernaola E, Pocheville I et al Reduction in pediatric invasive pneumococcal disease in the Basque Country and Navarre, Spain, after introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 26, 303-310 (2007).
12. Calbo E, Díaz Á, Cañadell E et al.; Spanish Pneumococcal Infection Study Network. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin. Microbiol. Infect. 12, 867-872 (2006).
13. Barricarte A, Castilla J, Gil-Setas A et al Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin. Infect. Dis. 44, 1436-1441 (2007).
14. Van der Ende A, Spanjaard L. The epidemiology of invasive pneumococcal disease in The Netherlands one year after the introduction of the heptavalent pneumococcal conjugate vaccine. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
15. Hanquet G, Kissling E, Fenoll A et al. Pneumococcal serotypes in children in 4 European countries. Emerg. Infect. Dis. 16, 1428-1439 (2010).
16. Black S, Shinefeld H, Baxter R et al Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23, 485-489 (2004).
17. Kyaw MH, Lynfeld R, Schaffner W et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354, 1455-1463 (2006).
18. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 8, 785-795 (2008).
19. Poehling KA, Lafeur BJ, Szilagyi PG et al. Population-based impact of pneumococcal conjugate vaccine in young children. Pediatrics 114, 755-761 (2004).
20. Poehling KA, Szilagyi PG, Grijalva G et al Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119, 707-715 (2007).
21. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffn MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369, 1179-1186 (2007).
22. Poehling KA, Talbot TR, Griffn MR et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295, 1668-1674 (2006).
23. European Medicines Agency. Assessment Report for Synforix. Procedure No. EMEA/H/C/000973. 1-61 (2009).
24. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children -Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal Wkly Rep. 59, 258-261 (2010).
25. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349, 1341-1348 (2003).
26. Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specifc pneumococcal anticapsular immunoglobulin G concerntrations after immunization with a 9-valent conjugate pneumococcal vaccine correlate with nasopharyngeal acquisition of pneumococcus. J. Infect. Dis. 192, 367-376 (2005).
27. Prymula R, Chlibek R, Splino M et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus infuenzae-derived protein D in the frst 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus infuenzae type b and control hepatitis A vaccines. Vaccine 26, 4563-4570 (2008).
28. Lucero MG, Nohynek H, Williams G et al Effcacy of an 11-valent pneumococcal conjugate vaccine against radiologically confrmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. Pediatr. Infect. Dis. J. 28, 455-462 (2009).
29. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis. 46, 174-182 (2008).
30. Park IH, Pritchard DG, Cartee R et al Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J. Clin. Microbiol. 45, 1225-1233 (2007).
31. Henriques-Normark B, Blomberg C, Dagerhamn J, Bättig P, Normark S. The rise and fall of bacterial clones: Streptococcus pneumoniae. Nat. Rev. Microbiol. 6, 827-837 (2008).
32. Choi EH, Kim SH, Eun BW et al Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14, 275-281 (2008).
33. Jefferson T, Ferroni E, Curtale F, Rossi PG, Borgia P. Streptococcus pneumoniae in western Europe: serotype distribution and incidence in children less than 2 years old. Lancet Infect. Dis. 6, 405-410 (2006).
34. Obaro S. Seven-valent pneumococcal conjugate vaccines for developing countries. Expert. Rev. Vaccines 8, 1051-1061 (2009).
35. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines 8, 1351-1364 (2009).
36. Hausdorff WP, Hajjeh R, Al-Mazrou A, Shibl A, Soriano-Gabarro M; The Middle East & North Africa (MENA) Vaccine-Preventable Diseases Regional Advisory Group. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region -current status and needs. Vaccine 25, 1935-1944 (2007).
37. Hausdorff WP, Siber G, Paradiso PR. Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children. Lancet 357, 950-952 (2001).
38. Hausdorff WP, Bryant J, Paradiso PR, Siber GR. Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I. Clin. Infect. Dis. 30, 100-121 (2000). (Pubitemid 30067069)
39. O'Brien KL, Wolfson LJ, Watt JP et al Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374, 893-902 (2009).
40. Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27, 7257-7269 (2009).
41. Rendi-Wagner P, Paulke-Korinek M, Kundi M et al. National paediatric immunization program of high risk groups: no effect on the incidence of invasive pneumococcal diseases. Vaccine 27, 3963-3968 (2009).
42. Guzvinec M, Tesovi G, Tambi-Andrasevi A, Zidovec-Lepej S, Vuki BT, Begovac J. The epidemiology of invasive Streptococcus pneumoniae disease in Croatian children. Med. Sci. Monit. 14, PH59-PH64 (2008).
43. De Carvalho Gomes H, Muscat M, Monnet DL, Giesecke J. Lopalco PL. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007 Euro. Surveill. 14, pii: 19159 (2009).
44. Motlova J, Benes C, Kriz P. Incidence of invasive pneumococcal disease in the Czech Republic and serotype coverage by vaccines, 1997-2006. Epidemiol. Infect. 137, 562-569 (2009).
45. Winther TN, Kristensen TD, Kaltoft MS, Konradsen HB, Knudsen JD, Høgh B. Invasive pneumococcal disease in Danish children, 1996-2007, prior to the introduction of heptavalent pneumococcal conjugate vaccine. Acta Paediatr. 98, 328-331 (2009).
46. Harboe ZB, Thomsen RW, Riis A et al Pneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort study. PLoS Med. 6, e1000081 (2009).
47. Lepoutre A, Varon E, Georges S, Gutmann L, Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro. Surveill. 13 (2008).
48. Bingen E, Levy C, Varon E et al.; The Bacterial Meningitis Study Group. Pneumococcal meningitis in the era of pneumococcal conjugate vaccine implementation. Eur. J. Clin. Microbiol. Infect. Dis. 27, 191-199 (2008).
49. Varon E, Gutmann L; Centre National de Référence des Pneumocoques. Rapport Dactivité 2007. Laboratoire de Microbiologie, Paris, France (2006).
50. Rückinger S, von Kries R, Reinert RR, Van der Linden M, Siedler A. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination. Vaccine 26, 3984-3986 (2008).
51. Rückinger S, Van der Linden M, Reinert RR, Von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27, 4136-4141 (2009).
52. Dias R, Caniça M. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine. FEMS Immunol. Med. Microbiol. 51, 35-42 (2007).
53. Pérez-Trallero E, Marimon JM, Ercibengoa M, Vicente D, Pérez-Yarza EG. Invasive Streptococcus pneumoniae infections in children and older adults in the north of Spain before and after the introduction of the heptavalent pneumococcal conjugate vaccine. Eur. J. Clin. Microbiol. Infect. Dis. 28, 731-738 (2009).
54. Arliles F, Horcajada I, Cañas AM et al Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands). Infect. Dis. Clin. Microbiol. 27, 14-21 (2009).
55. Guevara M, Barricarte A, Gil-Setas A et al Changing epidemiology of invasive pneumococcal disease following increased coverage with the heptavalent conjugate vaccine in Navarre, Spain. Clin. Microbiol Infect. 15, 1013-1019 (2009).
56. Reis JN, Cordeiro SM, Coppola SJ et al. Population-based survey of antimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae from meningitis patients in Salvador, Brazil. J. Clin. Microbiol. 40, 275-277 (2002).
57. Pérez A, Herranz M, Segura M et al Epidemiologic impact of blood culture practices and antibiotic consumption on pneumococcal bacteraemia in children. Eur. J. Clin. Microbiol. Infect. Dis. 27, 717-724 (2008).
58. Giele C, Moore H, Bayley K et al. Has the seven-valent pneumococcal conjugate vaccine had an impact on invasive pneumococcal disease in Western Australia? Vaccine 25, 2379-2384 (2007).
59. Song J-H, Baek J-Y, Cheong HS, Chung DR, Peck KR, Ko KS. Changes of serotype and genotype in Streptococcus pneumoniae isolates from a Korean hospital in 2007 Diagn. Microbiol. Infect. Dis. 63, 271-278 (2009).
60. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrell GJ, Scheifele DW Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-Area Streptococcus pneumoniae Research (CASPER) study. Clin. Infect. Dis. 49, 205-212 (2009).
61. Pilishvili T, Lexau C, Farley M et al.; Active Bacterial Core Surveillance/Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis. 201, 32-41 (2010).
62. Rendi-Wagner P, Georgopoulos A, Kundi M et al. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria. J. Antimicrob. Chemother. 53, 826-831 (2004).
63. Vergison A, Tuerlinckx D, Verhaegen J et al.; Belgian Invasive Pneumococcal Disease Study Group. Epidemiologic features of invasive pneumococcal disease in Belgian children: passive surveillance is not enough. Pediatrics 118, e801-e809 (2006).
64. Motlova J, Benes I, Kfízová P. Invasive pneumococcal disease in the Czech Republic in 2000-2006 [in Czech]. Epidemiol. Mikrobiol. Imunol. 57, 14-21 (2008).
65. Harboe ZB, Velentiner-Branth P, Benfeld TL et al. Estimated effect of pneumococcal conjugate vaccination on invasive pneumococcal disease and associated mortality, Denmark 2000-2005. Vaccine 26, 3765-3771 (2008).
66. Klemets P, Lyytikäinen O, Ruutu P et al. Trends and geographical variation in invasive pneumococcal infections in Finland. Scand. J. Infect. Dis. 40, 621-628 (2008).
67. Bruce MG, Deeks SL, Zulz T et al.; International Circumpolar Surveillance System for Invasive Pneumococcal Disease Working Group. International circumpolar surveillance system for invasive pneumococcal disease, 1999-2005. Emerg. Infect. Dis. 14, 25-33 (2008).
68. Imöhl M, Reinert RR, Van der Linden M. Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states. Int. J. Med. Microbiol. 300(4), 237-247 (2010).
69. Zissis NP, Syriopoulou V, Kafetzis D et al. Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive infections and acute otitis media in children. Eur. J. Pediatr. 163, 364-368 (2004).
70. Spanjaard L, Van Der Ende A, Rümke H, Dankert J, Van Alphen L. Epidemiology of meningitis and bacteraemia due to Streptococcus pneumoniae in The Netherlands. Acta Paediatr. Suppl. 435, 22-26 (2000).
71. Vestrheim DF, Høiby EA, Bergsaker MR, Rønning K, Aaberge IS, Caugant DA. Indirect effect of conjugate pneumococcal vaccination in a 2 + 1 dose schedule. Vaccine 28, 2214-2221 (2010).
72. Grzesiowski P, Skoczynska A, Albrecht P et al.; Polish Pediatric IPD Group. Invasive pneumococcal disease in children up to 5 years of age in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 27, 883-885 (2008).
73. Paragi M, Kolman J, Kraigher A, Aizman M, Gubina M, Ribi H; Slovenian Meningitis Study Group. Possibility of application of new pneumococcal conjugate vaccines in children in Slovenia. Vaccine 21, 4708-4714 (2003).
74. Sanz JC, Ramos B, Ochoa D et al. Serotype distribution of invasive Streptococcus pneumoniae isolates in Madrid one year after heptavalent pneumococcal conjugate vaccine (PCV7) introduction into the childhood vaccination calendar. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
75. Picazo J, Ruiz-Contreras J, Mendez C et al. Serotype distribution of invasive pneumococcal isolates among hospitalized children after systematic use of PCV7 in Madrid, Spain (HERACLES Study). Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008.
76. Casado-Flores J, Rodrigo C, Arístegui J, Martínón JM, Fenoll A, Mendez C. Decline in pneumococcal meningitis in Spain after the introduction of the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 27, 1020-1022 (2008).
77. Zucs P, Hauser C, Masserey V, Mühlemann K. Pneumococcal conjugate vaccination as an individual option -epidemiological impact of a new type of recommendation in Switzerland. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
78. Yalçin I, Gürler N, Alhan E et al. Serotype distribution and antibiotic susceptibility of invasive Streptococcus pneumoniae disease isolates from children in Turkey 2001-2004. Eur. J. Pediatr. 165, 654-657 (2006).
79. Slack M, Kaye P, George R, Borrow R, Andrews N, Miller E; Health Protection Agency Centre for Infections, UK. The impact of the introduction of the pneumococcal conjugate vaccine (PCV) programme for children in England and Wales - the frst two years. Presented at: Nordic Vaccine Meeting. Mariehamn, Åland, Finland, 4-5 September 2008.
80. Ihekweazu CA, Dance DAB, Pebody R et al.; South West Pneumococcus Study Group. Trends in incidence of pneumococcal disease before introduction of conjugate vaccine: South West England, 1996-2005. Epidemiol. Infect. 136, 1096-1012 (2007).
81. Foster D, Knox K, Walker AS et al.; Oxford Invasive Pneumococcal Surveillance Group. Invasive pneumococcal disease: epidemiology in children and adults prior to implementation of the conjugate vaccine in the Oxfordshire region, England. J. Med. Microbiol. 57, 480-487 (2008).
82. Youssef FG, El-Sakka H, Azab A et al. Etiology, antimicrobial susceptibility profles, and mortality associated with bacterial meningitis among children in Egypt. Ann. Epidemiol. 14, 44-48 (2004).
83. Elsaid MF, Flamerzi AA, Bessisso MS, Elshafe SS. Acute bacterial meningitis in Qatar. Saudi Med. J. 27, 204-210 (2006).
84. Al-Mazrou Y, Musa EK, Abdalla MN, Al-Jeffri MH, Al-Hajjar SH, Mohamed OM. Disease burden and case management of bacterial meningitis among children under 5 years of age in Saudi Arabia. Saudi Med. J. 24, 1300-1307 (2003).
85. Al-Mazrou YY, Al-Jeffri MH, Al-Haggar SH, Musa EK, Mohamed OM, Abdalla MN. Haemophilus type B meningitis in Saudi children under 5 years old. J. Trop. Pediatr. 50, 131-136 (2004).
86. Memish Z, Alotaibi B, Al al Shaalan M, Alola S, Althaqaf AH. A retrospective epidemiological study of invasive pneumococcal disease in children aged 0-5 years in the Kingdom of Saudi Arabia. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
87. Al-Mazrou A, Twum-Danso K, Al Zamil F, Kambal A. Streptococcus pneumoniae serotypes/serogroups causing invasive disease in Riyadh, Saudi Arabia: extent of coverage by pneumococcal vaccines. Ann. Saudi Med. 25, 94-99 (2005).
88. Maalej SM, Kassis M, Rhimi FM, Damak J, Hammami A. [Bacteriology of community acquired meningitis in Sfax, Tunisia (1993-2001)]. Méd. Mal. Infect. 36, 105-110 (2006).
89. Tregnaghi M, Ceballos A, Rüttimann R et al. Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr. Infect. Dis. J. 25, 370-372 (2006).
90. Garcia S, Levine OS, Cherian T, Gabastou JM, Andrus J; Working Group members. Pneumococcal disease and vaccination in the Americas: an agenda for accelerated vaccine introduction. Rev. Panam. Salud Publica 19, 340-348 (2006).
91. Tregnaghi M, Ceballos A, Ruttiman R, Hausdorff W, Ussher J, Yudouski S. Evolution of pneumococcal serotype distribution over a 5 year period in 1-35 month old children in the city of Cordoba, Argentina. Presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases. Alice Springs, Australia, 2-6 April 2006.
92. Andrade ALSS, Oliveira R, Vieira MA et al. Active epidemiologic surveillance of invasive pneumococcal disease (IPD) and chest radiograph (CXR) confrmed pneumonia (CXR+Pn) in children in Goiânia, Brazil. Presented at: 13th Latin American Congress of Pediatric Infectious Diseases. Guayaquil, Ecuador, 13-15 May 2009.
93. Levine MM, Lagos R, Levine OS et al. Epidemiology of invasive pneumococcal infections in infants and young children in Metropolitan Santiago, Chile, a newly industrializing country. Pediatr. Infect. Dis. J. 17, 287-293 (1998).
94. Lagos R, San Martin O, Erazo A, Avendaño A, Levine MM; Grupo de Trabajo Colaborativo Para el Diagnóstico de Infecciones Pneumocóccicas del Niño. Epidemiologia de las enfermedades invasoras causadas por Streptococcus pneumoniae en niños chilenos: proyecciones clinicas y de salud pública. Rev. Chil. Infect. 18, 15-21 (2001).
95. Lagos R, Muñoz A, San Martin O, Heitmann I, Loyola H, Levine MM. Secular variations in age incidence (Inc) and serotypes (St) causing invasive pneumococcal disease (IPD) in children 0 to 59 months of age (MoA) in the Metropolitan Region (MR), Chile. Presented at: 5th International Symposium on Pneumococci and Pneumococcal Diseases. Alice Springs, Australia, 2-6 April 2006.
96. Lagos R, Muñoz A, San Martin O et al. Age-and serotype-specifc pediatric invasive pneumococcal disease: insights from systematic surveillance in Santiago, Chile, 1994-2007. J. Infect. Dis. 198, 1809-1817 (2008).
97. Inostroza J, Vinet AM, Retamal G et al. Infuence of patient age on Streptococcus pneumoniae serotypes causing invasive disease. Clin. Diagn. Lab. Immunol. 8, 556-559 (2001).
98. Inostroza J, Illesca V, Reydet P et al. Ten-year surveillance of pneumococcal infections in Temuco, Chile: implications for vaccination strategies. Clin. Vaccine Immunol. 14, 660-664 (2007).
99. Lagos R, Muñoz A, Valenzuela T, Heitmann I, Levine MM. Population-based surveillance for hospitalized and ambulatory pediatric invasive pneumococcal disease in Santiago, Chile. Pediatr. Infect. Dis. J. 21, 1115-1123 (2002).
100. Abarca VK, Vergara FR, Tassara PE, Ibíñez WI, García BC, Potin SM. [Invasive pneumococcal disease and consolidated pneumonia in infants: one year of surveillance in three Chilean health care centers]. Rev. Chil. Infect. 25, 97-103 (2008).
101. Benavides JA, Reyes C, Flitter M, Markowitz J, Rodgers GL. Epidemiologic surveillance of invasive pneumococcal disease (IPD) and chest radiograph (CXR)-confrmed pneumonia (CXR+Pn) in children in Bogota, Colombia. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
102. Ulloa-Gutierrez R, Avila-Aguero ML, Herrera ML, Herrera JF, Arguedas A. Invasive pneumococcal disease in Costa Rican children: a seven year survey. Pediatr. Infect. Dis. J. 22, 1069-1074 (2003).
103. Arguedas A, Abdelnour A, Soley C et al. Active epidemiologic surveillance of invasive pneumococcal disease (IPD) and chest radiograph (CXR)-confrmed pneumonia (CXR+Pn) in children in San Jose, Costa Rica. Presented at: 2nd Vaccine Global Congress. Boston, MA, USA, 7-9 December 2008.
104. Ochoa TJ, Egoavil M, Castillo M et al. High mortality rates of invasive pneumococcal disease (IPD) in hospitalized children in Lima, Peru. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
105. Pírez-García MC, Larraz GG, Rostagno CR et al. [Invasive pneumococcal pneumonia in children 0 to 24 months: does bacterial resistance affect outcome?] An. Pediatr. (Barc.) 69, 205-209 (2008).
106. Torzillo PJ, Morey F, Gratten M, Murphy D, Matters R, Dixon J. Changing epidemiology of invasive pneumococcal disease in central Australia prior to conjugate vaccine: a 16-year study. Vaccine 25, 2375-2378 (2007).
107. Hanna JN, Humphreys JL, Murphy DM. Invasive pneumococcal disease in Indigenous people in north Queensland: an update, 2005-2007. Med. J. Aust. 189, 43-46 (2008).
108. Watson M, Roche P, Bayley K et al. Laboratory surveillance of invasive pneumococcal disease in Australia, 2003 -predicting the future impact of the universal childhood conjugate vaccine program. Commun. Dis. Intell. 28, 455-464 (2004).
109. Moore H. Recent increase in invasive pneumococcal disease, especially non-vaccine types, in non-Aboriginal children and adults in Western Australia. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
110. Brooks WA, Breiman RF, Goswami D et al. Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am. J. Trop. Med. Hyg. 7 7, 795-801 (2007).
111. Arifeen SE, Saha SK, Rahman S et al. Invasive pneumococcal disease among children in rural Bangladesh: results from a population-based surveillance. Clin. Infect. Dis. 48, S103-S113 (2009).
112. Wan R, Feng M. [Diagnosis of 104 cases of purulent meningitis in children]. Guizhou Med. J. 28, 417-419 (2004).
113. Li WM. [Clinical analysis of 30 cases of pyogenic meningitis]. Chin. J. Prim. Med. Pharm. 11, 203-204, (2004).
114. Wang Y, Wang C-Q, Wang X-H. [Etiology and antimicrobial susceptibility of children with bacterial meningitis]. J. Appl. Clin. Pediatr. 21, 355-356 (2006).
115. Liu Y, Wang H, Chen M et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn. Microbiol. Infect. Dis. 61, 256-263 (2008).
116. Ho PL, Lam KF, Chow FKH et al. Serotype distribution and antimicrobial resistance patterns of nasopharyngeal and invasive Streptococcus pneumoniae isolates in Hong Kong children. Vaccine 22, 3334-3339 (2004).
117. Ishiwada N, Kurosaki T, Terashima I, Kohno Y. The incidence of pediatric invasive pneumococcal disease in Chiba prefecture, Japan (2003-2005). J. Infect. 57, 455-458 (2008).
118. Shah AS, Knoll MD, Sharma PR et al. Invasive pneumococcal disease in Kanti Children's Hospital, Nepal, as observed by the South Asian Pneumococcal Alliance Network. Clin. Infect. Dis. 48, S123-S128 (2009).
119. Williams EJ, Thorson S, Maskey M et al. Hospital-based surveillance of invasive pneumococcal disease among young children in urban Nepal. Clin. Infect. Dis. 48, S114-S122 (2009).
120. Heffernan HM, Martin DR, Woodhouse RE, Morgan J, Blackmore TK. Invasive pneumococcal disease in New Zealand 1998-2005: capsular serotypes and antimicrobial resistance. Epidemiol. Infect. 136, 352-359 (2008).
121. Zaidi AKM, Khan H, Lasi R, Mahesar W; Sindh Meningitis Group. Surveillance of pneumococcal meningitis among children in Sindh, Southern Pakistan. Clin. Infect. Dis. 48, S129-S135 (2009).
122. Chong CY, Koh-Cheng T, Ye-Hui M, Nancy T W. Invasive pneumococcal disease in Singapore children. Vaccine 26, 3427-3431 (2008).
123. Siu LK, Chu M-L, Ho M, Lee Y-S, Wang C-C. Epidemiology of invasive pneumococcal infection in Taiwan: antibiotic resistance, serogroup distribution, and ribotypes analyses. Microb. Drug Resist. 8, 201-208 (2002).
124. Lauderdale T-L, Wagener MM, Lin HM et al. Serotype and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from Taiwanese children: comparison of nasopharyngeal and clinical isolates. Diagn. Microbiol. Infect. Dis. 56, 421-426 (2006).
125. Lin W-J, Lo W-T, Chou C-Y et al. Antimicrobial resistance patterns and serotype distribution of invasive Streptococcus pneumoniae isolates from children in Taiwan from 1999 to 2004. Diagn. Microbiol. Infect. Dis. 56, 189-196 (2006).
126. Chen Y-Y, Yao S-M, Chou C-Y et al. Surveillance of invasive Streptococcus pneumoniae in Taiwan, 2002-2003. J. Med. Microbiol. 55, 1109-1114 (2006).
127. Hsieh Y-C, Lin P-Y, Chiu C-H et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine 27, 5513-5518 (2009).
128. Baggett HC, Peruski LF, Olsen SJ et al. Incidence of pneumococcal bacteremia requiring hospitalization in rural Thailand. Clin. Infect. Dis. 48, S65-S74 (2009).
129. Anh DD, Kilgore PE, Slack MPE et al. Surveillance of pneumococcal- associated disease among hospitalized children in Khanh Hoa Province, Vietnam. Clin. Infect. Dis. 48, S57-S64 (2009).
130. Traore Y, Tameklo TA, Njanpop-Lafourcade B-M et al. Incidence, seasonality, age distribution, and mortality of pneumococcal meningitis in Burkina Faso and Togo. Clin. Infect. Dis. 84, S181-S189 (2009).
131. Leimkugel J, Forgor AA, Gagneux S et al. An outbreak of serotype 1 Streptococcus pneumoniae meningitis in northern Ghana with features that are characteristic of Neisseria meningitidis meningitis epidemics. J. Infect. Dis. 192, 192-199 (2005).
132. Feikin DR, Jagero G, Aura B et al. High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya. BMC Infect. Dis. 10, 186 (2010).
133. Campbell JD, Kotloff KL, Sow SO et al. Invasive pneumococcal infections among hospitalized children in Bamako, Mali. Pediatr. Infect. Dis. J. 23, 642-649 (2004).
134. Roca A, Bassat Q, Morais L et al. Surveillance of acute bacterial meningitis among children admitted to a district hospital in rural Mozambique. Clin. Infect. Dis. 48, S172-S180 (2009).
135. Kisakye A, Makumbi I, Nansera D et al. Surveillance for Streptococcus pneumoniae meningitis in children
136. Bjornson GL, Scheifele DW, Halperin SA; Canadian Paediatric Society/Health Canada Immunization Monitoring Program, Active (IMPACT). Population-based epidemiology of invasive pneumococcal infection in children in nine urban centers in Canada, 1994 through 1998. Pediatr. Infect. Dis. J. 21, 947-950 (2002).
137. National Advisory Committee on Immunization (NACI). An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Statement on recommended use of pneumococcal conjugate vaccine. Can. Commun. Dis. Rep. 28, 1-32 (2002).
138. Tyrell GJ, Lovgren M, Chui N et al. Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre-and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006. Vaccine 27, 3553-3560 (2009).
139. Winters M, Patrick DM, Marra F et al. Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine. Can. J. Public Health 99, 57-61 (2008).
140. Gubbay JB, Green K, Pong-Porter S et al. Impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in children in Toronto and Peel Regions, Ontario, Canada. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
141. Hsu K, Pelton S, Karumuri S, Heisey-Grove D, Klein J; Massachusetts Department of Public Health Epidemiologists. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr. Infect. Dis. J. 24, 17-23 (2004).
142. Lacapa R, Bliss SJ, Larzelere-Hinton F et al. Changing epidemiology of invasive pneumococcal disease among White Mountain Apache persons in the era of the pneumococcal conjugate vaccine. Clin. Infect. Dis. 47, 476-484 (2008).
143. Stephens DS, Zughaier SM, Whitney CG et al.; Georgia Emerging Infections Program. Incidence of macrolide resistance in Streptococcus pneumoniae after
144. Tsai CJ, Griffn MR, Nuorti JP, Grijalva CG. Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin. Infect. Dis. 46, 1664-1672 (2008).
145. Singleton RJ, Hennessy TW, Bulkow LR et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska Native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297, 1784-1792 (2007).
146. Byington CL, Samore MH, Stoddard GJ et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin. Infect. Dis. 41, 21-29 (2005).
147. Black S, France EK, Isaacman D et al Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26, 771-777 (2007).
148. Albrich WC, Baughman W, Schmotzer B, Farley MM. Changing characteristics of invasive pneumococcal disease in Metropolitan Atlanta, Georgia, after introduction of a 7-valent pneumococcal conjugate vaccine. Clin. Infect. Dis. 44, 1569-1576 (2007).
149. Whitney CG, Farley MM, Hadler J et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348, 1737-1746 (2003).
150. Lexau CA, Lynfeld R, Danila R et al.; Active Bacterial Core Surveillance Team. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294, 2043-2051 (2005).
151. Herz AM, Greenhow TL, Alcantara J et al. Changing epidemiology of outpatient bacteremia in 3-to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. Pediatr. Infect. Dis. J. 25, 293-300 (2006).
152. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196, 1346-1354 (2007).
153. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction -eight states, 1998-2005. MMWR Morb. Mortal. Wkly Rep. 57, 144-148 (2008).
154. Schuchat A, Pilishvili T, Farley M et al Near elimination of vaccine-type invasive pneumococcal disease in U.S. following conjugate vaccine implementation, 1998-2006. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
155. Talbot TR, Poehling KA, Hartert TV et al. Reduction in high rates of antibiotic-nonsusceptible invasive pneumococcal disease in Tennessee after introduction of the pneumococcal conjugate vaccine. Clin. Infect. Dis. 39, 641-648 (2004).
156. Haddy RI, Perry K, Chacko CE et al. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr. Infect. Dis. J. 24, 320-323 (2005).
157. Pai R, Moore MR, Pilishvili T et al.; Active Bacterial Core Surveillance Team. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192, 1988-1995 (2005).
158. Beall B, McEllistrem MC, Gertz RE et al.; Active Bacterial Core Surveillance Team. Pre-and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J. Clin. Microbiol. 44, 999-1017 (2006).
159. Steenhoff AP, Shah SS, Ratner AJ, Patil SM, McGowan KL. Emergence of vaccine-related pneumococcal serotypes as a cause of bacteremia. Clin. Infect. Dis. 42, 907-914 (2006).
160. Messina AF, Katz-Gaynor K, Barton T et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatr. Infect. Dis. J. 26, 461-467 (2007).
161. Hsu KK, Shea KM, Stevenson AE, Pelton SI; Members of the Massachusetts Department of Public Health. Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007. Pediatr. Infect. Dis. J. 29, 289-293 (2010).
162. Hanage WP, Kaijalainen TH, Syrjänen RK et al. Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in Finland. Infect. Immun. 73, 431-435 (2005).
163. Imöhl M, Van Der Linden M, Mutscher C, Reinert RR. Serotype distribution of invasive pneumococccal disease during the frst 60 days of life. Vaccine 28, 4758-4762 (2010).
164. Paraskakis I, Charisiadou A, Kyrikou H et al. Emergence of 7F and 19A serotypes in invasive pneumococcal diseases in childhood in Greece after the introduction of pneumococcal vaccination. Presented at: 26th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID). Graz, Austria, 13-17 May 2008.
165. Koutouzis E, Daikos GL, Roma E et al. Streptococcus pneumoniae serotypes before and after introduction of pneumococcal conjugate vaccine in Greece. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
166. Aguiar SI, Serrano I, Pinto FR, Melo-Cristino J, Ramirez M; Portuguese Surveillance Group for the Study of Respiratory Pathogens. Changes in Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination coverage of the seven-valent conjugate vaccine. Clin. Microbiol. Infect. 14, 835-843 (2008).
167. Serrano I, Ramirez M, Melo-Cristino J; Portuguese Surveillance Group for the Study of Respiratory Pathogens. Invasive Streptococcus pneumoniae from Portugal: implications for vaccination and antimicrobial therapy. Clin. Microbiol. Infect. 10, 652-656 (2004).
168. Rodrigues F, Nunes S, Sá-Leão R, Gonçalves G, Lemos L, de Lencastre H. Streptococcus pneumoniae nasopharyngeal carriage in children attending day-care centers in the central region of Portugal, in the era of 7-valent pneumococcal conjugate vaccine. Microb. Drug Resist. 15, 269-277 (2009).
169. Salleras L, Domínguez A, Ciruela P et al. Changes in serotypes causing pneumococcal disease (2005-2007 vs. 1997-199) in children under 2 years of age in a population with intermediate coverage of the 7-valent pneumococcal conjugated vaccine. Clin. Microbiol. Infect. 15, 997-1001 (2009).
170. Ceyhan M, Yildirim I, Sheppard CL, George RC. Pneumococcal serotypes causing pediatric meningitis in Turkey: application of a new technology in the investigation of cases negative by conventional culture. Eur. J. Clin. Microbiol. Infect. Dis. 29, 289-293 (2010).
171. Shibl AM. Distribution of serotypes and antibiotic resistance of invasive pneumococcal disease isolates among children aged 5 years and under in Saudi Arabia (2000-2004). Clin. Microbiol. Infect. 14, 876-879 (2008).
172. Ruvinsky R. [Epidemiology of invasive infections caused by Streptococcus pneumoniae in Argentina: a surveillance system, 1993-2004]. Rev. Hosp. Ninos Baires 47, 222-232 (2005).
173. Castañeda E, Agudelo CI, Regueira M et al.; SIREVA II Group. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr. Infect. Dis. J. 28, e265-e270 (2009).
174. Vieira AC, Gomes MC, Filho MR, Filho JE, Bello EJM, de Figueiredo RB. Streptococcus pneumoniae: a study of strains isolated from cerebrospinal fuid. J. Pediatr. (Rio J.) 83, 71-78 (2007).
175. Mantese OC, de Paula A, Almeida VV et al. Prevalence of serotypes and antimicrobial resistance of invasive strains of pneumococcus in children: analysis of 9 years. J. Pediatr. 85, 495-502 (2009).
176. Andrade ALSS, Oliveira R, Vieira MA et al. Active epidemiologic surveillance of invasive pneumococcal disease (IPD) and chest radiograph (CXR) confrmed pneumonia (CXR+ Pn) in children in Goiania, Brazil. Presented at: 13th Latin American Congress of Pediatric Infectious Diseases. Guayaquil, Ecuador, 13-15 May 2009.
177. Saha SK, Naheed A, Arifeen SE et al.; Pneumococcal Study Group. Surveillance for invasive Streptococcus pneumoniae disease among hospitalized children in Bangladesh: antimicrobial susceptibility and serotype distribution. Clin. Infect. Dis. 48, S75-S81 (2009).
178. Ubukata K, Chiba N, Hasegawa K, Kobayashi R, Iwata S, Sunakawa K. Antibiotic susceptibility in relation to penicillin-binding protein genes and serotype distribution of Streptococcus pneumoniae strains responsible for meningitis in Japan, 1999 to 2002. Antimicrob. Agents Chemother. 48, 1488-1494 (2004).
179. Chiba N, Morozumi M, Sunaoshi K et al.; IPD Surveillance Study Group. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol. Infect. 138, 61-68 (2009).
180. Choi E-H, Lee H-J. Clinical outcome of invasive infections by penicillin-resistant Streptococcus pneumoniae in Korean children. Clin. Infect. Dis. 26, 1346-1354 (1998).
181. Rohani MY, Raudzah A, Ng AJ et al. Epidemiology of Streptococcus pneumoniae infection in Malaysia. Epidemiol. Infect. 122, 77-82 (1999).
182. Kim SW, Capeding MRZ, Sombrero LT, Kim S, Kilgore P, Herrera G. Serotype distribution of invasive S. pneumoniae in Filipino children, 2000-2007. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
183. Batuwanthudawe R, Karunarathne K, Dassanayake M et al. Surveillance of invasive pneumococcal disease in Colombo, Sri Lanka. Clin. Infect. Dis. 48, S136-S140 (2009).
184. Hsieh Y-C, Hsueh P-R, Lu C-Y, Lee P-I, Lee C-Y, Huang L-M. Clinical manifestations and molecular epidemiology of necrotizing pneumonia and empyema caused by Streptococcus pneumoniae in children in Taiwan. Clin. Infect. Dis. 38, 830-835 (2004).
185. Levine S, Dejsirilert S, Sangsuk L et al. Serotypes and antimicrobial resistance of Streptococcus pneumoniae in Thailand 2002-2004. Pediatr. Infect. Dis. J. 25, 176-178 (2006).
186. Adegbola RA, Hill PC, Secka O et al. Serotype and antimicrobial susceptibility patterns of isolates of Streptococcus pneumoniae causing invasive disease in The Gambia 1996-2003. Trop. Med. Int. Health 11, 1128-1135 (2006).
187. Antonio M, Dada-Adegbola H, Biney E et al. Molecular epidemiology of pneumococci obtained from Gambian children aged 2-29 months with invasive pneumococcal disease during a trial of a 9-valent pneumococcal conjugate vaccine. BMC Infect. Dis. 8, 81-90 (2008).
188. Jetté L, Bourgault A-M, Raynal L, De Wals P. Impact of 7-valent pneumococcal conjugate (PCV7) on serotype distribution and susceptibility profles of invasive S. pneumoniae (ISp) isolates in Quebec. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
189. Hennessy TW, Singleton RJ, Bulkow LR et al. Impact of heptavalent pneumococcal conjugate vaccine on invasive disease, antimicrobial resistance and colonization in Alaska Natives: progress towards elimination of a health disparity. Vaccine 23, 5464-5473 (2005).
190. Ivády B, Pásztor M. [Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae strains isolated from middle ear fuids of children aged 0-24 months with acute otitis media]. Orv. Hetil. 150, 935-941 (2009).
191. Gherardi G, D'Ambrosio F, Monaco M et al. Population structure of invasive Streptococcus pneumoniae isolates in Italy prior to the implementation of the 7-valent conjugate vaccine (1999-2003). Eur. J. Clin. Microbiol. Infect. Dis. 28, 99-103 (2009).
192. Fitzgerald M, Murchan S, Cotter S, Vickers I, Cafferkey M. Pneumococcal typing in Ireland - a pilot project. EPI-Insight: Dis. Surveill. Rep. (HPSC, Ireland) 9, 1-4 (2008).
193. Flamaing J, Verhaegen J, Vandeven J, Verbiest N, Peetermans WE. Pneumococcal bacteraemia in Belgium (1994-2004): the pre-conjugate vaccine era. J. Antimicrob. Chemother. 61, 143-149 (2008).
194. Amrine-Madsen H, Van Eldere J, Mera RM et al. Temporal and spatial distribution of clonal complexes of Streptococcus pneumoniae isolates resistant to multiple classes of antibiotics in Belgium, 1997 to 2004. Antimicrob. Agents Chemother. 52, 3216-3220 (2008).
195. Siira L, Rantala M, Jalava J et al. Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006. Antimicrob. Agents Chemother. 53, 2066-2073 (2009).
196. Grivea IN, Panagiotou M, Tsantouli AG, Syrogiannopoulos GA. Impact of heptavalent pneumococcal conjugate vaccine on nasopharyngeal carriage of penicillin-resistant Streptococcus pneumoniae among day-care center attendees in central Greece. Pediatr. Infect. Dis. J. 27, 519-515 (2008).
197. Bergsaker MAR, Feiring B. Introduction of pneumococcal conjugate vaccine into the Norwegian childhood vaccination programme. Euro. Surveill. 11(2), E060202.5 (2006).
198. Nowosiad M, Giedrys-Kalemba S. Resistance, serotype and genetic diversity of Streptococcus pneumoniae-resistant strains isolated in the West Pomerania region of Poland in the years 2001-2005. Eur. J. Clin. Microbiol. Infect. Dis. 27, 769-777 (2008).
199. Center KJ. Prevenar™ vaccination: review of the global data, 2006. Vaccine 25, 3085-3089 (2007).
200. Fenoll A, Granizo JJ, Aguilar L et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007 J. Clin. Microbiol. 47, 1012-1020 (2009).
201. Muhlemann K, Aebi S. Carriage of Streptococcus pneumoniae in Swiss infants, 2001-2007 Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
202. Farrell DJ, Felmingham D, Shackcloth J et al.; BSAC Working Parties on Resistance Surveillance. Non-susceptibility trends and serotype distributions among Streptococcus pneumoniae from community-acquired respiratory tract infections and from bacteraemias in the UK and Ireland, 1999 to 2007. J. Antimicrob. Chemother. 62, ii87-ii95 (2008).
203. Ruvinsky RO, Regueira M, Corso A et al. Streptococcus pneumoniae (Spn) invasive diseases: surveillance of serotypes in children in Argentina. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
204. Vieira AC, Gomes MC, Rolo Filho M, Filho E, Bello EJ, de Figueiredo RB. Streptococcus pneumoniae: a study of strains isolated from cerebrospinal fuid. J. Pediatr. (Rio J.) 83, 71-78 (2007).
205. Egoavil M, Ochoa T, Reyes I et al.; Grupo Peruano de Investigación en Neumococo. Serotipos de Streptococcus pneumoniae en pacientes pediátricos con enfermedad invasiva en Lima-Perú. Presented at: 12th Congress of the Latin American Society of Pediatric Infectious Diseases (SLIPE). Costa Rica, 8-11 May 2007.
206. Hortal M, Sehabiague G, Camou T, Iraola I, Estevan M, Pujadas M. Pneumococcal pneumonia in hospitalized Uruguayan children and potential prevention with different vaccine formulations. J. Pediatr. 152, 850-853 (2008).
207. Zhao G-M, Black S, Shinefeld H et al. Serotype distribution and antimicrobial resistance patterns in Streptococcus pneumoniae isolates from hospitalized pediatric patients with respiratory infections in Shanghai, China. Pediatr. Infect. Dis. J. 22, 739-742 (2003).
208. Mastro TD, Ghafoor A, Nomani NK et al. Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet 337, 156-159 (1991).
209. Lehmann D, Willis J, Moore H et al. Increase in incidence of invasive pneumococcal disease due to non-7-valent vaccine serotypes in Aboriginal adults in Western Australia following introduction of pneumococcal conjugate vaccine in children. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
210. Saha SK, Baqui AH, Darmstadt GL et al. Comparison of antibiotic resistance and serotype composition of carriage and invasive pneumococci among Bangladeshi children: implications for treatment policy and vaccine formulation. J. Clin. Microbiol. 41, 5582-5587 (2003).
211. Liu Z, Yao K, Yu S, Yuan L, Yang Y. Epidemiology of serogroup 6 Streptococcus pneumoniae isolates from children in Beijing, China. Presented at: 7th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Bangkok, Thailand, 18-20 March 2009.
212. Xue L, Yao KH, Liu ZJ, Yu SJ, Yang YH. Antibiotic resistance of serotype 19A Streptococcus pneumoniae isolated from children in Beijing Children's Hospital, 2000-2007. Presented at: 7th International Symposium on Antimicrobial Agents and Resistance (ISAAR). Bangkok, Thailand, 18-20 March 2009.
213. Capeding MRZ, Sombrero LT, Lucero MG, Saniel MC. Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Filipino children. J. Infect. Dis. 169, 479-480 (1994).
214. Lee CK, Liu JW, Leu HS, Jian CJ, Li CC. Streptococcus pneumoniae bacteremia in southern Taiwan. J. Microbiol. Immunol. Infect. 35, 17-22 (2002).
215. Feikin DR, Davis M, Nwanyanwu OC et al. Antibiotic resistance and serotype distribution of Streptococcus pneumoniae colonizing rural Malawian children. Pediatr. Infect. Dis. J. 22, 564-567 (2003).
216. Hill PC, Cheung YB, Akisanya A et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Gambian infants: a longitudinal study. Clin. Infect. Dis. 46, 807-814 (2008).
217. Blossom DB, Cordeiro SM, Bajaksouzian S et al. Characterization of penicillin intermediate serotypes of Streptococcus pneumoniae carried by human immunodefciency virus-infected adults and healthy children in Uganda. Microb. Drug Resist. 13, 21-28 (2007).
218. Kellner JD, Scheifele D, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ. Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with Streptococcus pneumoniae in children in Calgary, Canada. Pediatr. Infect. Dis. J. 27, 526-532 (2008).
219. De Wals P, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J. 27, 963-968 (2008).
220. De Wals P, Jetté L, Sévin S et al. Changes in the epidemiology of invasive pneumococcal disease (IPD) following implementation of a 7-valent pneumococcal conjugate vaccine (PCV7) program in Quebec, Canada. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
221. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26, 468-472 (2007).
222. Whitney CG, Pilishvili T, Farley MM et al. Long-term effect of 7-valent pneumococcal conjugate vaccine (PCV7) use on invasive pneumococcal disease (IPD) in the U.S. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. Washington, DC, USA, 25-28 October 2008.
223. Da Gloria Carvalho M, Gertz R, Li Z, Moore M, Beall B; Active Bacterial Core Surveillance. Population-based strain surveillance of invasive serotype 19A pneumococci recovered in the United States: 2006. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
224. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196, 1346-1354 (2007).
225. Mera R, Miller LA, Fritsche TR, Jones RN. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microbiol. Drug Resist. 14, 101-107 (2008).
226. Jacobs MR, Good CE, Beall B, Bajaksouzian S, Windau AR, Whitney CG. Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J. Clin. Microbiol. 46, 982-990 (2008).
227. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin. Infect. Dis. 47, 1388-1395 (2008).
228. Moore MR, Gertz RE, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197, 1016-1027 (2008).
229. Singleton R, Holman R, Yorita K et al. Pneumococcal empyema and pleural effusion among Alaska native children less than 10 years of age. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
230. Nurkka A, Åhman H, Korkeila M, Jäntti V, Kähty H, Eskola J. Serum and salivary anti-capsular antibodies ininfants and chldren immunized with the heptavalent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 20, 25-33 (2001). (Pubitemid 32066172)
231. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine -United States, 1997-2006. MMWR Morb. Mortal. Wkly. Rep. 58, 1-4 (2009).
232. Johnson HL, Deloria-Knoll M, Levine OS et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under fve: the Pneumococcal Global Serotype Project. PLoS Med. 7, e1000348 (2010).
233. Black S. The volatile nature of pneumococcal serotype epidemiology. Potential for misinterpretation. Pediatr. Infect. Dis. J. 29, 301-303 (2010).
234. Harboe ZB, Benfeld TL, Valentiner-Branth P et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin. Infect. Dis. 50, 329-337 (2010).
235. Park IH, Moore MR, Treanor et al. Reduction in serotype 6A invasive pneumococcal disease after accounting for effect of serotype 6A. Presented at: 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD). Reykjavik, Iceland, 8-12 June 2008.
236. World Health Organization. Pneumococcal conjugate vaccine for childhood immunization -WHO position paper. Wkly Epidemiol. Rec. 12, 93-104 (2007).
237. Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. Proc. Natl Acad. Sci. USA 96, 1152-1156 (1999).
238. Pneumo ADIP. Strategic Demand Forecast History 2003-2008. May 2009.